Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD).

Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field.

With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages.

First-in-human studies are planned within 18 months with our lead candidate.

We are committed to developing effective therapies for the benefit of the patients.